198 related articles for article (PubMed ID: 29616409)
1. Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe?
Francisco ARG; Alves D; David C; Guerra L; Pinto FJ; Almeida AG
Cardiovasc Toxicol; 2018 Oct; 18(5):431-435. PubMed ID: 29616409
[TBL] [Abstract][Full Text] [Related]
2. Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.
Karakulak UN; Aladag E; Hekimsoy V; Sahiner ML; Kaya EB; Ozer N; Aksu S; Demiroglu H; Goker H; Buyukasik Y; Ozcebe O; Sayinalp N; Haznedaroglu IC
Cardiovasc Toxicol; 2021 Mar; 21(3):216-223. PubMed ID: 33068232
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
5. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
[No Abstract] [Full Text] [Related]
6. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.
Petrikova L; Slezakova K; Sninska Z; Harvanova L; Martisova M; Hatalova A; Mistrik M; Batorova A; Mladosievicova B
Bratisl Lek Listy; 2021; 122(8):531-537. PubMed ID: 34282617
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.
Lai GM; Yan SL; Chang CS; Tsai CY
World J Gastroenterol; 2013 Feb; 19(8):1318-21. PubMed ID: 23483799
[TBL] [Abstract][Full Text] [Related]
9. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
[TBL] [Abstract][Full Text] [Related]
10. Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Casavecchia G; Spinosa G; De Gennaro L; Zicchino S; Gravina M; Magnesa M; Di Biase M; Brunetti ND
Acta Cardiol; 2022 Apr; 77(2):130-135. PubMed ID: 33685352
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
Novo G; Di Lisi D; Bronte E; Macaione F; Accurso V; Badalamenti G; Rinaldi G; Siragusa S; Novo S; Russo A
Oncology; 2020; 98(7):445-451. PubMed ID: 32348984
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.
Durand MJ; Hader SN; Derayunan A; Zinkevich N; McIntosh JJ; Beyer AM
Microcirculation; 2020 Oct; 27(7):e12625. PubMed ID: 32395853
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
14. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
[TBL] [Abstract][Full Text] [Related]
15. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
16. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
Molica M; Scalzulli E; Colafigli G; Fegatelli DA; Massaro F; Latagliata R; Foà R; Breccia M
Ann Hematol; 2018 Oct; 97(10):1803-1808. PubMed ID: 29806063
[TBL] [Abstract][Full Text] [Related]
17. Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib.
Leitão JR; Valente NY; Kakizaki P; Veronez IS; Pires MC
An Bras Dermatol; 2016; 91(5 suppl 1):45-47. PubMed ID: 28300891
[TBL] [Abstract][Full Text] [Related]
18. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
Guérin A; Chen L; Ionescu-Ittu R; Marynchenko M; Nitulescu R; Hiscock R; Keir C; Wu EQ
Curr Med Res Opin; 2014 Nov; 30(11):2317-28. PubMed ID: 25025755
[TBL] [Abstract][Full Text] [Related]
19. Should vascular effects of newer treatments be addressed more completely?
Yang EH; Watson KE; Herrmann J
Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
[No Abstract] [Full Text] [Related]
20. Assessment of Imatinib as a Primary Treatment of Chronic Myeloid Leukemia in Chronic Phase: a Cohort Study.
Merin D; Krishna A; Jayakumar S; Mahima A; Anila KN; Sidharthan N
J Oncol Pharm Pract; 2023 Apr; 29(3):547-556. PubMed ID: 35048760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]